Literature references that cite this PDB file's
key reference
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
E.A.Verderio,
A.Scarpellini,
and
T.S.Johnson
(2009).
Novel interactions of TG2 with heparan sulfate proteoglycans: reflection on physiological implications.
|
| |
Amino Acids, 36,
671-677.
|
 |
|
|
|
|
 |
E.S.Place,
N.D.Evans,
and
M.M.Stevens
(2009).
Complexity in biomaterials for tissue engineering.
|
| |
Nat Mater, 8,
457-470.
|
 |
|
|
|
|
 |
E.Stuttfeld,
and
K.Ballmer-Hofer
(2009).
Structure and function of VEGF receptors.
|
| |
IUBMB Life, 61,
915-922.
|
 |
|
|
|
|
 |
J.Jia,
M.Maccarana,
X.Zhang,
M.Bespalov,
U.Lindahl,
and
J.P.Li
(2009).
Lack of L-iduronic acid in heparan sulfate affects interaction with growth factors and cell signaling.
|
| |
J Biol Chem, 284,
15942-15950.
|
 |
|
|
|
|
 |
J.Moreaux,
A.C.Sprynski,
S.R.Dillon,
K.Mahtouk,
M.Jourdan,
A.Ythier,
P.Moine,
N.Robert,
E.Jourdan,
J.F.Rossi,
and
B.Klein
(2009).
APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop.
|
| |
Eur J Haematol, 83,
119-129.
|
 |
|
|
|
|
 |
K.Iwao,
M.Inatani,
Y.Matsumoto,
M.Ogata-Iwao,
Y.Takihara,
F.Irie,
Y.Yamaguchi,
S.Okinami,
and
H.Tanihara
(2009).
Heparan sulfate deficiency leads to Peters anomaly in mice by disturbing neural crest TGF-beta2 signaling.
|
| |
J Clin Invest, 119,
1997-2008.
|
 |
|
|
|
|
 |
M.Zakrzewska,
A.Wiedlocha,
A.Szlachcic,
D.Krowarsch,
J.Otlewski,
and
S.Olsnes
(2009).
Increased protein stability of FGF1 can compensate for its reduced affinity for heparin.
|
| |
J Biol Chem, 284,
25388-25403.
|
 |
|
|
|
|
 |
S.Ashikari-Hada,
H.Habuchi,
N.Sugaya,
T.Kobayashi,
and
K.Kimata
(2009).
Specific inhibition of FGF-2 signaling with 2-O-sulfated octasaccharides of heparan sulfate.
|
| |
Glycobiology, 19,
644-654.
|
 |
|
|
|
|
 |
S.Li,
C.Christensen,
L.B.Køhler,
V.V.Kiselyov,
V.Berezin,
and
E.Bock
(2009).
Agonists of fibroblast growth factor receptor induce neurite outgrowth and survival of cerebellar granule neurons.
|
| |
Dev Neurobiol, 69,
837-854.
|
 |
|
|
|
|
 |
A.Kochoyan,
F.M.Poulsen,
V.Berezin,
E.Bock,
and
V.V.Kiselyov
(2008).
Structural basis for the activation of FGFR by NCAM.
|
| |
Protein Sci, 17,
1698-1705.
|
 |
|
|
|
|
 |
D.G.Seidler,
and
R.Dreier
(2008).
Decorin and its galactosaminoglycan chain: extracellular regulator of cellular function?
|
| |
IUBMB Life, 60,
729-733.
|
 |
|
|
|
|
 |
K.R.Catlow,
J.A.Deakin,
Z.Wei,
M.Delehedde,
D.G.Fernig,
E.Gherardi,
J.T.Gallagher,
M.S.Pavão,
and
M.Lyon
(2008).
Interactions of hepatocyte growth factor/scatter factor with various glycosaminoglycans reveal an important interplay between the presence of iduronate and sulfate density.
|
| |
J Biol Chem, 283,
5235-5248.
|
 |
|
|
|
|
 |
K.Tan,
M.Duquette,
J.H.Liu,
K.Shanmugasundaram,
A.Joachimiak,
J.T.Gallagher,
A.C.Rigby,
J.H.Wang,
and
J.Lawler
(2008).
Heparin-induced cis- and trans-dimerization modes of the thrombospondin-1 N-terminal domain.
|
| |
J Biol Chem, 283,
3932-3941.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
M.E.Levenstein,
W.T.Berggren,
J.E.Lee,
K.R.Conard,
R.A.Llanas,
R.J.Wagner,
L.M.Smith,
and
J.A.Thomson
(2008).
Secreted proteoglycans directly mediate human embryonic stem cell-basic fibroblast growth factor 2 interactions critical for proliferation.
|
| |
Stem Cells, 26,
3099-3107.
|
 |
|
|
|
|
 |
N.Fukuhara,
J.A.Howitt,
S.A.Hussain,
and
E.Hohenester
(2008).
Structural and functional analysis of slit and heparin binding to immunoglobulin-like domains 1 and 2 of Drosophila Robo.
|
| |
J Biol Chem, 283,
16226-16234.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
N.S.Gandhi,
and
R.L.Mancera
(2008).
The structure of glycosaminoglycans and their interactions with proteins.
|
| |
Chem Biol Drug Des, 72,
455-482.
|
 |
|
|
|
|
 |
N.Sugaya,
H.Habuchi,
N.Nagai,
S.Ashikari-Hada,
and
K.Kimata
(2008).
6-O-sulfation of heparan sulfate differentially regulates various fibroblast growth factor-dependent signalings in culture.
|
| |
J Biol Chem, 283,
10366-10376.
|
 |
|
|
|
|
 |
S.J.Goodger,
C.J.Robinson,
K.J.Murphy,
N.Gasiunas,
N.J.Harmer,
T.L.Blundell,
D.A.Pye,
and
J.T.Gallagher
(2008).
Evidence that heparin saccharides promote FGF2 mitogenesis through two distinct mechanisms.
|
| |
J Biol Chem, 283,
13001-13008.
|
 |
|
|
|
|
 |
S.Mori,
C.Y.Wu,
S.Yamaji,
J.Saegusa,
B.Shi,
Z.Ma,
Y.Kuwabara,
K.S.Lam,
R.R.Isseroff,
Y.K.Takada,
and
Y.Takada
(2008).
Direct binding of integrin alphavbeta3 to FGF1 plays a role in FGF1 signaling.
|
| |
J Biol Chem, 283,
18066-18075.
|
 |
|
|
|
|
 |
T.Muramatsu,
and
H.Muramatsu
(2008).
Glycosaminoglycan-binding cytokines as tumor markers.
|
| |
Proteomics, 8,
3350-3359.
|
 |
|
|
|
|
 |
V.N.Patel,
K.M.Likar,
S.Zisman-Rozen,
S.N.Cowherd,
K.S.Lassiter,
I.Sher,
E.A.Yates,
J.E.Turnbull,
D.Ron,
and
M.P.Hoffman
(2008).
Specific heparan sulfate structures modulate FGF10-mediated submandibular gland epithelial morphogenesis and differentiation.
|
| |
J Biol Chem, 283,
9308-9317.
|
 |
|
|
|
|
 |
W.Zhang,
Y.Chen,
M.R.Swift,
E.Tassi,
D.C.Stylianou,
K.A.Gibby,
A.T.Riegel,
and
A.Wellstein
(2008).
Effect of FGF-binding Protein 3 on Vascular Permeability.
|
| |
J Biol Chem, 283,
28329-28337.
|
 |
|
|
|
|
 |
C.Morlot,
N.M.Thielens,
R.B.Ravelli,
W.Hemrika,
R.A.Romijn,
P.Gros,
S.Cusack,
and
A.A.McCarthy
(2007).
Structural insights into the Slit-Robo complex.
|
| |
Proc Natl Acad Sci U S A, 104,
14923-14928.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
C.R.Holst,
H.Bou-Reslan,
B.B.Gore,
K.Wong,
D.Grant,
S.Chalasani,
R.A.Carano,
G.D.Frantz,
M.Tessier-Lavigne,
B.Bolon,
D.M.French,
and
A.Ashkenazi
(2007).
Secreted sulfatases Sulf1 and Sulf2 have overlapping yet essential roles in mouse neonatal survival.
|
| |
PLoS ONE, 2,
e575.
|
 |
|
|
|
|
 |
E.Sandilands,
S.Akbarzadeh,
A.Vecchione,
D.G.McEwan,
M.C.Frame,
and
J.K.Heath
(2007).
Src kinase modulates the activation, transport and signalling dynamics of fibroblast growth factor receptors.
|
| |
EMBO Rep, 8,
1162-1169.
|
 |
|
|
|
|
 |
K.Park,
Y.S.Kim,
G.Y.Lee,
J.O.Nam,
S.K.Lee,
R.W.Park,
S.Y.Kim,
I.S.Kim,
and
Y.Byun
(2007).
Antiangiogenic effect of bile acid acylated heparin derivative.
|
| |
Pharm Res, 24,
176-185.
|
 |
|
|
|
|
 |
N.Kulahin,
V.Kiselyov,
A.Kochoyan,
O.Kristensen,
J.S.Kastrup,
V.Berezin,
E.Bock,
and
M.Gajhede
(2007).
Structure of rat acidic fibroblast growth factor at 1.4 A resolution.
|
| |
Acta Crystallogr Sect F Struct Biol Cryst Commun, 63,
65-68.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
N.Salamat-Miller,
J.Fang,
C.W.Seidel,
Y.Assenov,
M.Albrecht,
and
C.R.Middaugh
(2007).
A network-based analysis of polyanion-binding proteins utilizing human protein arrays.
|
| |
J Biol Chem, 282,
10153-10163.
|
 |
|
|
|
|
 |
P.M.Smallwood,
J.Williams,
Q.Xu,
D.J.Leahy,
and
J.Nathans
(2007).
Mutational analysis of Norrin-Frizzled4 recognition.
|
| |
J Biol Chem, 282,
4057-4068.
|
 |
|
|
|
|
 |
T.Derrick,
A.O.Grillo,
S.N.Vitharana,
L.Jones,
J.Rexroad,
A.Shah,
M.Perkins,
T.M.Spitznagel,
and
C.R.Middaugh
(2007).
Effect of polyanions on the structure and stability of repifermin (keratinocyte growth factor-2).
|
| |
J Pharm Sci, 96,
761-776.
|
 |
|
|
|
|
 |
T.Kobayashi,
H.Habuchi,
K.Tamura,
H.Ide,
and
K.Kimata
(2007).
Essential role of heparan sulfate 2-O-sulfotransferase in chick limb bud patterning and development.
|
| |
J Biol Chem, 282,
19589-19597.
|
 |
|
|
|
|
 |
V.Vreys,
and
G.David
(2007).
Mammalian heparanase: what is the message?
|
| |
J Cell Mol Med, 11,
427-452.
|
 |
|
|
|
|
 |
W.D.Tolbert,
J.Daugherty,
C.Gao,
Q.Xie,
C.Miranti,
E.Gherardi,
G.V.Woude,
and
H.E.Xu
(2007).
A mechanistic basis for converting a receptor tyrosine kinase agonist to an antagonist.
|
| |
Proc Natl Acad Sci U S A, 104,
14592-14597.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
A.Canales,
R.Lozano,
B.López-Méndez,
J.Angulo,
R.Ojeda,
P.M.Nieto,
M.Martín-Lomas,
G.Giménez-Gallego,
and
J.Jiménez-Barbero
(2006).
Solution NMR structure of a human FGF-1 monomer, activated by a hexasaccharide heparin-analogue.
|
| |
FEBS J, 273,
4716-4727.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
A.Canales-Mayordomo,
R.Fayos,
J.Angulo,
R.Ojeda,
M.Martín-Pastor,
P.M.Nieto,
M.Martín-Lomas,
R.Lozano,
G.Giménez-Gallego,
and
J.Jiménez-Barbero
(2006).
Backbone dynamics of a biologically active human FGF-1 monomer, complexed to a hexasaccharide heparin-analogue, by 15N NMR relaxation methods.
|
| |
J Biomol NMR, 35,
225-239.
|
 |
|
|
|
|
 |
A.E.Harrington,
S.A.Morris-Triggs,
B.T.Ruotolo,
C.V.Robinson,
S.Ohnuma,
and
M.Hyvönen
(2006).
Structural basis for the inhibition of activin signalling by follistatin.
|
| |
EMBO J, 25,
1035-1045.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
E.Gherardi,
S.Sandin,
M.V.Petoukhov,
J.Finch,
M.E.Youles,
L.G.Ofverstedt,
R.N.Miguel,
T.L.Blundell,
G.F.Vande Woude,
U.Skoglund,
and
D.I.Svergun
(2006).
Structural basis of hepatocyte growth factor/scatter factor and MET signalling.
|
| |
Proc Natl Acad Sci U S A, 103,
4046-4051.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
E.Sanchez-Heras,
F.V.Howell,
G.Williams,
and
P.Doherty
(2006).
The fibroblast growth factor receptor acid box is essential for interactions with N-cadherin and all of the major isoforms of neural cell adhesion molecule.
|
| |
J Biol Chem, 281,
35208-35216.
|
 |
|
|
|
|
 |
J.Lee,
V.K.Dubey,
T.Somasundaram,
and
M.Blaber
(2006).
Conversion of type I 4:6 to 3:5 beta-turn types in human acidic fibroblast growth factor: effects upon structure, stability, folding, and mitogenic function.
|
| |
Proteins, 62,
686-697.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
L.Duchesne,
B.Tissot,
T.R.Rudd,
A.Dell,
and
D.G.Fernig
(2006).
N-glycosylation of fibroblast growth factor receptor 1 regulates ligand and heparan sulfate co-receptor binding.
|
| |
J Biol Chem, 281,
27178-27189.
|
 |
|
|
|
|
 |
L.L.Kiessling,
J.E.Gestwicki,
and
L.E.Strong
(2006).
Synthetic multivalent ligands as probes of signal transduction.
|
| |
Angew Chem Int Ed Engl, 45,
2348-2368.
|
 |
|
|
|
|
 |
L.Ling,
S.Murali,
C.Dombrowski,
L.M.Haupt,
G.S.Stein,
A.J.van Wijnen,
V.Nurcombe,
and
S.M.Cool
(2006).
Sulfated glycosaminoglycans mediate the effects of FGF2 on the osteogenic potential of rat calvarial osteoprogenitor cells.
|
| |
J Cell Physiol, 209,
811-825.
|
 |
|
|
|
|
 |
L.M.McDowell,
B.A.Frazier,
D.R.Studelska,
K.Giljum,
J.Chen,
J.Liu,
K.Yu,
D.M.Ornitz,
and
L.Zhang
(2006).
Inhibition or activation of Apert syndrome FGFR2 (S252W) signaling by specific glycosaminoglycans.
|
| |
J Biol Chem, 281,
6924-6930.
|
 |
|
|
|
|
 |
M.A.Dupree,
S.R.Pollack,
E.M.Levine,
and
C.T.Laurencin
(2006).
Fibroblast growth factor 2 induced proliferation in osteoblasts and bone marrow stromal cells: a whole cell model.
|
| |
Biophys J, 91,
3097-3112.
|
 |
|
|
|
|
 |
N.A.Oliveira,
L.G.Alonso,
R.D.Fanganiello,
and
M.R.Passos-Bueno
(2006).
Further evidence of association between mutations in FGFR2 and syndromic craniosynostosis with sacrococcygeal eversion.
|
| |
Birth Defects Res A Clin Mol Teratol, 76,
629-633.
|
 |
|
|
|
|
 |
N.Jastrebova,
M.Vanwildemeersch,
A.C.Rapraeger,
G.Giménez-Gallego,
U.Lindahl,
and
D.Spillmann
(2006).
Heparan sulfate-related oligosaccharides in ternary complex formation with fibroblast growth factors 1 and 2 and their receptors.
|
| |
J Biol Chem, 281,
26884-26892.
|
 |
|
|
|
|
 |
R.Sasisekharan,
R.Raman,
and
V.Prabhakar
(2006).
Glycomics approach to structure-function relationships of glycosaminoglycans.
|
| |
Annu Rev Biomed Eng, 8,
181-231.
|
 |
|
|
|
|
 |
S.A.Hussain,
M.Piper,
N.Fukuhara,
L.Strochlic,
G.Cho,
J.A.Howitt,
Y.Ahmed,
A.K.Powell,
J.E.Turnbull,
C.E.Holt,
and
E.Hohenester
(2006).
A molecular mechanism for the heparan sulfate dependence of slit-robo signaling.
|
| |
J Biol Chem, 281,
39693-39698.
|
 |
|
|
|
|
 |
T.L.Blundell,
B.L.Sibanda,
R.W.Montalvão,
S.Brewerton,
V.Chelliah,
C.L.Worth,
N.J.Harmer,
O.Davies,
and
D.Burke
(2006).
Structural biology and bioinformatics in drug design: opportunities and challenges for target identification and lead discovery.
|
| |
Philos Trans R Soc Lond B Biol Sci, 361,
413-423.
|
 |
|
|
|
|
 |
V.V.Kiselyov,
A.Kochoyan,
F.M.Poulsen,
E.Bock,
and
V.Berezin
(2006).
Elucidation of the mechanism of the regulatory function of the Ig1 module of the fibroblast growth factor receptor 1.
|
| |
Protein Sci, 15,
2318-2322.
|
 |
|
|
|
|
 |
V.V.Kiselyov,
E.Bock,
V.Berezin,
and
F.M.Poulsen
(2006).
NMR structure of the first Ig module of mouse FGFR1.
|
| |
Protein Sci, 15,
1512-1515.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
Y.Luo,
S.Ye,
M.Kan,
and
W.L.McKeehan
(2006).
Control of fibroblast growth factor (FGF) 7- and FGF1-induced mitogenesis and downstream signaling by distinct heparin octasaccharide motifs.
|
| |
J Biol Chem, 281,
21052-21061.
|
 |
|
|
|
|
 |
Y.Luo,
S.Ye,
M.Kan,
and
W.L.McKeehan
(2006).
Structural specificity in a FGF7-affinity purified heparin octasaccharide required for formation of a complex with FGF7 and FGFR2IIIb.
|
| |
J Cell Biochem, 97,
1241-1258.
|
 |
|
|
|
|
 |
A.A.Anderson,
C.E.Kendal,
M.Garcia-Maya,
A.V.Kenny,
S.A.Morris-Triggs,
T.Wu,
R.Reynolds,
E.Hohenester,
and
J.L.Saffell
(2005).
A peptide from the first fibronectin domain of NCAM acts as an inverse agonist and stimulates FGF receptor activation, neurite outgrowth and survival.
|
| |
J Neurochem, 95,
570-583.
|
 |
|
|
|
|
 |
C.J.Robinson,
N.J.Harmer,
S.J.Goodger,
T.L.Blundell,
and
J.T.Gallagher
(2005).
Cooperative dimerization of fibroblast growth factor 1 (FGF1) upon a single heparin saccharide may drive the formation of 2:2:1 FGF1.FGFR2c.heparin ternary complexes.
|
| |
J Biol Chem, 280,
42274-42282.
|
 |
|
|
|
|
 |
F.Carinci,
F.Pezzetti,
P.Locci,
E.Becchetti,
F.Carls,
A.Avantaggiato,
A.Becchetti,
P.Carinci,
T.Baroni,
and
M.Bodo
(2005).
Apert and Crouzon syndromes: clinical findings, genes and extracellular matrix.
|
| |
J Craniofac Surg, 16,
361-368.
|
 |
|
|
|
|
 |
J.Kim,
J.Lee,
S.R.Brych,
T.M.Logan,
and
M.Blaber
(2005).
Sequence swapping does not result in conformation swapping for the beta4/beta5 and beta8/beta9 beta-hairpin turns in human acidic fibroblast growth factor.
|
| |
Protein Sci, 14,
351-359.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
K.Ingold,
A.Zumsteg,
A.Tardivel,
B.Huard,
Q.G.Steiner,
T.G.Cachero,
F.Qiang,
L.Gorelik,
S.L.Kalled,
H.Acha-Orbea,
P.D.Rennert,
J.Tschopp,
and
P.Schneider
(2005).
Identification of proteoglycans as the APRIL-specific binding partners.
|
| |
J Exp Med, 201,
1375-1383.
|
 |
|
|
|
|
 |
L.Jin,
P.E.Barran,
J.A.Deakin,
M.Lyon,
and
D.Uhrín
(2005).
Conformation of glycosaminoglycans by ion mobility mass spectrometry and molecular modelling.
|
| |
Phys Chem Chem Phys, 7,
3464-3471.
|
 |
|
|
|
|
 |
M.Baum,
S.Schiavi,
V.Dwarakanath,
and
R.Quigley
(2005).
Effect of fibroblast growth factor-23 on phosphate transport in proximal tubules.
|
| |
Kidney Int, 68,
1148-1153.
|
 |
|
|
|
|
 |
O.A.Ibrahimi,
B.K.Yeh,
A.V.Eliseenkova,
F.Zhang,
S.K.Olsen,
M.Igarashi,
S.A.Aaronson,
R.J.Linhardt,
and
M.Mohammadi
(2005).
Analysis of mutations in fibroblast growth factor (FGF) and a pathogenic mutation in FGF receptor (FGFR) provides direct evidence for the symmetric two-end model for FGFR dimerization.
|
| |
Mol Cell Biol, 25,
671-684.
|
 |
|
|
|
|
 |
T.Iwase,
C.G.Jung,
H.Bae,
M.Zhang,
and
B.Soliven
(2005).
Glial cell line-derived neurotrophic factor-induced signaling in Schwann cells.
|
| |
J Neurochem, 94,
1488-1499.
|
 |
|
|
|
|
 |
T.M.Handel,
Z.Johnson,
S.E.Crown,
E.K.Lau,
and
A.E.Proudfoot
(2005).
Regulation of protein function by glycosaminoglycans--as exemplified by chemokines.
|
| |
Annu Rev Biochem, 74,
385-410.
|
 |
|
|
|
|
 |
U.Häcker,
K.Nybakken,
and
N.Perrimon
(2005).
Heparan sulphate proteoglycans: the sweet side of development.
|
| |
Nat Rev Mol Cell Biol, 6,
530-541.
|
 |
|
|
|
|
 |
V.K.Dubey,
J.Lee,
and
M.Blaber
(2005).
Redesigning symmetry-related "mini-core" regions of FGF-1 to increase primary structure symmetry: thermodynamic and functional consequences of structural symmetry.
|
| |
Protein Sci, 14,
2315-2323.
|
 |
|
|
|
|
 |
C.Dodé,
and
J.P.Hardelin
(2004).
Kallmann syndrome: fibroblast growth factor signaling insufficiency?
|
| |
J Mol Med, 82,
725-734.
|
 |
|
|
|
|
 |
G.A.Nicolaes,
K.W.Sørensen,
U.Friedrich,
G.Tans,
J.Rosing,
L.Autin,
B.Dahlbäck,
and
B.O.Villoutreix
(2004).
Altered inactivation pathway of factor Va by activated protein C in the presence of heparin.
|
| |
Eur J Biochem, 271,
2724-2736.
|
 |
|
|
|
|
 |
K.Nogami,
H.Suzuki,
H.Habuchi,
N.Ishiguro,
H.Iwata,
and
K.Kimata
(2004).
Distinctive expression patterns of heparan sulfate O-sulfotransferases and regional differences in heparan sulfate structure in chick limb buds.
|
| |
J Biol Chem, 279,
8219-8229.
|
 |
|
|
|
|
 |
M.J.Bernett,
T.Somasundaram,
and
M.Blaber
(2004).
An atomic resolution structure for human fibroblast growth factor 1.
|
| |
Proteins, 57,
626-634.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
R.T.Böttcher,
N.Pollet,
H.Delius,
and
C.Niehrs
(2004).
The transmembrane protein XFLRT3 forms a complex with FGF receptors and promotes FGF signalling.
|
| |
Nat Cell Biol, 6,
38-44.
|
 |
|
|
|
|
 |
S.Wang,
X.Ai,
S.D.Freeman,
M.E.Pownall,
Q.Lu,
D.S.Kessler,
and
C.P.Emerson
(2004).
QSulf1, a heparan sulfate 6-O-endosulfatase, inhibits fibroblast growth factor signaling in mesoderm induction and angiogenesis.
|
| |
Proc Natl Acad Sci U S A, 101,
4833-4838.
|
 |
|
|
|
|
 |
Z.Shriver,
S.Raguram,
and
R.Sasisekharan
(2004).
Glycomics: a pathway to a class of new and improved therapeutics.
|
| |
Nat Rev Drug Discov, 3,
863-873.
|
 |
|
|
|
|
 |
B.K.Yeh,
M.Igarashi,
A.V.Eliseenkova,
A.N.Plotnikov,
I.Sher,
D.Ron,
S.A.Aaronson,
and
M.Mohammadi
(2003).
Structural basis by which alternative splicing confers specificity in fibroblast growth factor receptors.
|
| |
Proc Natl Acad Sci U S A, 100,
2266-2271.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
C.Fernández-Tornero,
R.M.Lozano,
M.Redondo-Horcajo,
A.M.Gómez,
J.C.López,
E.Quesada,
C.Uriel,
S.Valverde,
P.Cuevas,
A.Romero,
and
G.Giménez-Gallego
(2003).
Leads for development of new naphthalenesulfonate derivatives with enhanced antiangiogenic activity: crystal structure of acidic fibroblast growth factor in complex with 5-amino-2-naphthalene sulfonate.
|
| |
J Biol Chem, 278,
21774-21781.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
C.Ito,
Y.Saitoh,
Y.Fujita,
Y.Yamazaki,
T.Imamura,
S.Oka,
and
S.Suzuki
(2003).
Decapeptide with fibroblast growth factor (FGF)-5 partial sequence inhibits hair growth suppressing activity of FGF-5.
|
| |
J Cell Physiol, 197,
272-283.
|
 |
|
|
|
|
 |
E.Gherardi,
M.E.Youles,
R.N.Miguel,
T.L.Blundell,
L.Iamele,
J.Gough,
A.Bandyopadhyay,
G.Hartmann,
and
P.J.Butler
(2003).
Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor.
|
| |
Proc Natl Acad Sci U S A, 100,
12039-12044.
|
 |
|
|
|
|
 |
M.Borgenström,
M.Jalkanen,
and
M.Salmivirta
(2003).
Sulfated derivatives of Escherichia coli K5 polysaccharides as modulators of fibroblast growth factor signaling.
|
| |
J Biol Chem, 278,
49882-49889.
|
 |
|
|
|
|
 |
P.Lindblom,
H.Gerhardt,
S.Liebner,
A.Abramsson,
M.Enge,
M.Hellstrom,
G.Backstrom,
S.Fredriksson,
U.Landegren,
H.C.Nystrom,
G.Bergstrom,
E.Dejana,
A.Ostman,
P.Lindahl,
and
C.Betsholtz
(2003).
Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall.
|
| |
Genes Dev, 17,
1835-1840.
|
 |
|
|
|
|
 |
R.Raman,
G.Venkataraman,
S.Ernst,
V.Sasisekharan,
and
R.Sasisekharan
(2003).
Structural specificity of heparin binding in the fibroblast growth factor family of proteins.
|
| |
Proc Natl Acad Sci U S A, 100,
2357-2362.
|
 |
|
|
|
|
 |
S.K.Olsen,
M.Garbi,
N.Zampieri,
A.V.Eliseenkova,
D.M.Ornitz,
M.Goldfarb,
and
M.Mohammadi
(2003).
Fibroblast growth factor (FGF) homologous factors share structural but not functional homology with FGFs.
|
| |
J Biol Chem, 278,
34226-34236.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
S.R.Brych,
J.Kim,
T.M.Logan,
and
M.Blaber
(2003).
Accommodation of a highly symmetric core within a symmetric protein superfold.
|
| |
Protein Sci, 12,
2704-2718.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
T.Merkulova-Rainon,
P.England,
S.Ding,
C.Demerens,
and
G.Tobelem
(2003).
The N-terminal domain of hepatocyte growth factor inhibits the angiogenic behavior of endothelial cells independently from binding to the c-met receptor.
|
| |
J Biol Chem, 278,
37400-37408.
|
 |
|
|
|
|
 |
Z.L.Wu,
L.Zhang,
T.Yabe,
B.Kuberan,
D.L.Beeler,
A.Love,
and
R.D.Rosenberg
(2003).
The involvement of heparan sulfate (HS) in FGF1/HS/FGFR1 signaling complex.
|
| |
J Biol Chem, 278,
17121-17129.
|
 |
|
|
|
|
 |
A.K.Powell,
D.G.Fernig,
and
J.E.Turnbull
(2002).
Fibroblast growth factor receptors 1 and 2 interact differently with heparin/heparan sulfate. Implications for dynamic assembly of a ternary signaling complex.
|
| |
J Biol Chem, 277,
28554-28563.
|
 |
|
|
|
|
 |
A.O.Wilkie,
S.J.Patey,
S.H.Kan,
A.M.van den Ouweland,
and
B.C.Hamel
(2002).
FGFs, their receptors, and human limb malformations: clinical and molecular correlations.
|
| |
Am J Med Genet, 112,
266-278.
|
 |
|
|
|
|
 |
B.K.Yeh,
A.V.Eliseenkova,
A.N.Plotnikov,
D.Green,
J.Pinnell,
T.Polat,
A.Gritli-Linde,
R.J.Linhardt,
and
M.Mohammadi
(2002).
Structural basis for activation of fibroblast growth factor signaling by sucrose octasulfate.
|
| |
Mol Cell Biol, 22,
7184-7192.
|
 |
|
|
|
|
 |
B.M.Loo,
and
M.Salmivirta
(2002).
Heparin/Heparan sulfate domains in binding and signaling of fibroblast growth factor 8b.
|
| |
J Biol Chem, 277,
32616-32623.
|
 |
|
|
|
|
 |
C.Rolny,
D.Spillmann,
U.Lindahl,
and
L.Claesson-Welsh
(2002).
Heparin amplifies platelet-derived growth factor (PDGF)- BB-induced PDGF alpha -receptor but not PDGF beta -receptor tyrosine phosphorylation in heparan sulfate-deficient cells. Effects on signal transduction and biological responses.
|
| |
J Biol Chem, 277,
19315-19321.
|
 |
|
|
|
|
 |
D.G.Vanselow
(2002).
Role of constraint in catalysis and high-affinity binding by proteins.
|
| |
Biophys J, 82,
2293-2303.
|
 |
|
|
|
|
 |
D.McCabe,
T.Cukierman,
and
J.E.Gabay
(2002).
Basic residues in azurocidin/HBP contribute to both heparin binding and antimicrobial activity.
|
| |
J Biol Chem, 277,
27477-27488.
|
 |
|
|
|
|
 |
I.Capila,
and
R.J.Linhardt
(2002).
Heparin-protein interactions.
|
| |
Angew Chem Int Ed Engl, 41,
391-412.
|
 |
|
|
|
|
 |
J.D.Esko,
and
S.B.Selleck
(2002).
Order out of chaos: assembly of ligand binding sites in heparan sulfate.
|
| |
Annu Rev Biochem, 71,
435-471.
|
 |
|
|
|
|
 |
J.Kim,
S.I.Blaber,
and
M.Blaber
(2002).
Alternative type I and I' turn conformations in the beta8/beta9 beta-hairpin of human acidic fibroblast growth factor.
|
| |
Protein Sci, 11,
459-466.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
J.Kreuger,
T.Matsumoto,
M.Vanwildemeersch,
T.Sasaki,
R.Timpl,
L.Claesson-Welsh,
D.Spillmann,
and
U.Lindahl
(2002).
Role of heparan sulfate domain organization in endostatin inhibition of endothelial cell function.
|
| |
EMBO J, 21,
6303-6311.
|
 |
|
|
|
|
 |
J.M.Trowbridge,
J.A.Rudisill,
D.Ron,
and
R.L.Gallo
(2002).
Dermatan sulfate binds and potentiates activity of keratinocyte growth factor (FGF-7).
|
| |
J Biol Chem, 277,
42815-42820.
|
 |
|
|
|
|
 |
K.Tan,
M.Duquette,
J.H.Liu,
Y.Dong,
R.Zhang,
A.Joachimiak,
J.Lawler,
and
J.H.Wang
(2002).
Crystal structure of the TSP-1 type 1 repeats: a novel layered fold and its biological implication.
|
| |
J Cell Biol, 159,
373-382.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
P.F.Varela,
A.S.Llera,
R.A.Mariuzza,
and
J.Tormo
(2002).
Crystal structure of imaginal disc growth factor-2. A member of a new family of growth-promoting glycoproteins from Drosophila melanogaster.
|
| |
J Biol Chem, 277,
13229-13236.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
S.H.Kan,
N.Elanko,
D.Johnson,
L.Cornejo-Roldan,
J.Cook,
E.W.Reich,
S.Tomkins,
A.Verloes,
S.R.Twigg,
S.Rannan-Eliya,
D.M.McDonald-McGinn,
E.H.Zackai,
S.A.Wall,
M.Muenke,
and
A.O.Wilkie
(2002).
Genomic screening of fibroblast growth-factor receptor 2 reveals a wide spectrum of mutations in patients with syndromic craniosynostosis.
|
| |
Am J Hum Genet, 70,
472-486.
|
 |
|
|
|
|
 |
S.M.Prince,
M.Achtman,
and
J.P.Derrick
(2002).
Crystal structure of the OpcA integral membrane adhesin from Neisseria meningitidis.
|
| |
Proc Natl Acad Sci U S A, 99,
3417-3421.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
T.L.Blundell,
H.Jhoti,
and
C.Abell
(2002).
High-throughput crystallography for lead discovery in drug design.
|
| |
Nat Rev Drug Discov, 1,
45-54.
|
 |
|
|
|
|
 |
T.Sasaki,
P.G.Knyazev,
Y.Cheburkin,
W.Göhring,
D.Tisi,
A.Ullrich,
R.Timpl,
and
E.Hohenester
(2002).
Crystal structure of a C-terminal fragment of growth arrest-specific protein Gas6. Receptor tyrosine kinase activation by laminin G-like domains.
|
| |
J Biol Chem, 277,
44164-44170.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
B.L.Allen,
M.S.Filla,
and
A.C.Rapraeger
(2001).
Role of heparan sulfate as a tissue-specific regulator of FGF-4 and FGF receptor recognition.
|
| |
J Cell Biol, 155,
845-858.
|
 |
|
|
|
|
 |
C.W.Mandl,
H.Kroschewski,
S.L.Allison,
R.Kofler,
H.Holzmann,
T.Meixner,
and
F.X.Heinz
(2001).
Adaptation of tick-borne encephalitis virus to BHK-21 cells results in the formation of multiple heparan sulfate binding sites in the envelope protein and attenuation in vivo.
|
| |
J Virol, 75,
5627-5637.
|
 |
|
|
|
|
 |
D.Lietha,
D.Y.Chirgadze,
B.Mulloy,
T.L.Blundell,
and
E.Gherardi
(2001).
Crystal structures of NK1-heparin complexes reveal the basis for NK1 activity and enable engineering of potent agonists of the MET receptor.
|
| |
EMBO J, 20,
5543-5555.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
G.J.Strewler
(2001).
FGF23, hypophosphatemia, and rickets: has phosphatonin been found?
|
| |
Proc Natl Acad Sci U S A, 98,
5945-5946.
|
 |
|
|
|
|
 |
H.J.Hecht,
R.Adar,
B.Hofmann,
O.Bogin,
H.Weich,
and
A.Yayon
(2001).
Structure of fibroblast growth factor 9 shows a symmetric dimer with unique receptor- and heparin-binding interfaces.
|
| |
Acta Crystallogr D Biol Crystallogr, 57,
378-384.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
J.D.Esko,
and
U.Lindahl
(2001).
Molecular diversity of heparan sulfate.
|
| |
J Clin Invest, 108,
169-173.
|
 |
|
|
|
|
 |
J.T.Gallagher
(2001).
Heparan sulfate: growth control with a restricted sequence menu.
|
| |
J Clin Invest, 108,
357-361.
|
 |
|
|
|
|
 |
O.A.Ibrahimi,
A.V.Eliseenkova,
A.N.Plotnikov,
K.Yu,
D.M.Ornitz,
and
M.Mohammadi
(2001).
Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome.
|
| |
Proc Natl Acad Sci U S A, 98,
7182-7187.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
P.Bellosta,
A.Iwahori,
A.N.Plotnikov,
A.V.Eliseenkova,
C.Basilico,
and
M.Mohammadi
(2001).
Identification of receptor and heparin binding sites in fibroblast growth factor 4 by structure-based mutagenesis.
|
| |
Mol Cell Biol, 21,
5946-5957.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
R.V.Iozzo,
and
J.D.San Antonio
(2001).
Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena.
|
| |
J Clin Invest, 108,
349-355.
|
 |
|
|
|
|
 |
Z.Zhang,
C.Coomans,
and
G.David
(2001).
Membrane heparan sulfate proteoglycan-supported FGF2-FGFR1 signaling: evidence in support of the "cooperative end structures" model.
|
| |
J Biol Chem, 276,
41921-41929.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|